IPO - Profile


We are a clinical-stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (“WHO”) the U.S. Centers for Disease Control and Prevention (“CDC”) and the U.S. Food and Drug Administration (“FDA”). Priority pathogens are those which require new antibiotics to address the worldwide crisis of antimicrobial resistance (“AMR”) as identified by the WHO, CDC and FDA. The CDC estimates that, in the U.S., antibiotic-resistant pathogens infect one individual every 11 seconds and result in one death every More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$6.00 2,500,000 Positive High 567.2%

Offering Team

  • Legal counsel
  • Sullivan & Cromwell LLP
  • Auditors
  • CohnReznick LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 24 Jun, 2021

Offer 25 Jun, 2021

Look Ahead

Lock Up Expiry Dec 25, 2021

IPO Terms

Offer Price $6.00
Offer Size 2M

Market Sentiments

Stock Price